130 related articles for article (PubMed ID: 29562497)
1. Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.
Zhou X; Wang J; Xia J; Cheng F; Mao J; Zhu J; Guo H
Cancer Biomark; 2018; 22(1):43-48. PubMed ID: 29562497
[TBL] [Abstract][Full Text] [Related]
2. Limited Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratios in Elderly Patients with Multiple Myeloma.
Wang J; Wang J; Sun C; Xia J; Zhou X; Guo HF
Clin Lab; 2018 Apr; 64(4):507-513. PubMed ID: 29739072
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
[TBL] [Abstract][Full Text] [Related]
4. The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma.
Wongrakpanich S; George G; Chaiwatcharayut W; Biso S; Candelario N; Mittal V; Pomerantz S; Varadi G
J Clin Lab Anal; 2016 Nov; 30(6):1208-1213. PubMed ID: 27239981
[TBL] [Abstract][Full Text] [Related]
5. Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio.
Kelkitli E; Atay H; Cilingir F; Güler N; Terzi Y; Ozatlı D; Turgut M
Ann Hematol; 2014 May; 93(5):841-6. PubMed ID: 24337486
[TBL] [Abstract][Full Text] [Related]
6. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
7. The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma.
Lee GW; Park SW; Go SI; Kim HG; Kim MK; Min CK; Kwak JY; Bae SB; Yoon SS; Lee JJ; Kim KH; Nam SH; Mun YC; Kim HJ; Bae SH; Shin HJ; Lee JH; Park JS; Jeong SH; Lee MH; Lee HS; Park KW; Lee WS; Lee SM; Lee JO; Hyun MS; Jo DY; Lim SN; Lee JH; Kim H; Cho DY; Do YR; Kim JA; Park SK; Kim JS; Kim SJ; Yi HG; Moon JH; Choi CW; Kim SH; Kim BS; Park MR; Shim H; Song MK; Kim Y; Kim K
Acta Haematol; 2018; 140(3):146-156. PubMed ID: 30253397
[TBL] [Abstract][Full Text] [Related]
8. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma.
Shi L; Qin X; Wang H; Xia Y; Li Y; Chen X; Shang L; Tai YT; Feng X; Acharya P; Acharya C; Xu Y; Deng S; Hao M; Zou D; Zhao Y; Ru K; Qiu L; An G
Oncotarget; 2017 Mar; 8(12):18792-18801. PubMed ID: 27852046
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen.
Szudy-Szczyrek A; Mlak R; Mielnik M; Szczyrek M; Nowaczyńska A; Homa-Mlak I; Zmorzyński S; Kuśmierczuk K; Sompor J; Filip A; Małecka-Massalska T; Hus M
Ann Hematol; 2020 Dec; 99(12):2881-2891. PubMed ID: 32458064
[TBL] [Abstract][Full Text] [Related]
10. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience.
Onec B; Okutan H; Albayrak M; Saribacak Can E; Aslan V; Unver Koluman B; Soyer Kosemehmetoglu O; Albayrak A; Kos DM
J Clin Lab Anal; 2017 Mar; 31(2):. PubMed ID: 27500465
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the change in neutrophil-to-lymphocyte ratio during first-line palliative chemotherapy in patients with metastatic gastric cancer: A retrospective study.
Bozkurt O; Firat ST; Dogan E; Cosar R; Inanc M; Ozkan M
J BUON; 2019; 24(5):1992-1999. PubMed ID: 31786866
[TBL] [Abstract][Full Text] [Related]
13. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
16. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
19. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
